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1 Introduction
The prevention of premature uterine contrac-
tions and thus premature birth has been one
of the most important problems of perinatal
medicine for many years [1, 3, 4, 5, 7]. A rele-
vant and reproducible tocolysis with clinically
demonstrable effect has only been possible since
the development of relatively selective betai mi-
metics. This has been documented especially
for fenoterol in large number of studies in the
last 15 years [14].
Oral therapy with fenoterol is gernerally carried
out with 5 mg Partusisten tablets administered
at time intervals of three to six hours. To im-
prove compliance, a fenoterol depot form was
developed in order to make possible successful
oral therapy with an eight-hour (or night) pause
for taking the preparation.
Results of first clinical experience with such a
depot form are already available [2, 8, 11, 13].
In this study a randomization was carried out
at six centers in accordance with valid criteria,
and the effects and side effects of a fenoterol
depot preparation with delayed release of active
substance (designated as fenoterol depot) and
a fenoterol preparation with undelayed release
of active substance (designated as fenoterol)
randomized in accordance with valid criteria
and with the use of a double-blind method were
compared with an approximately equal overall
dose over a period of 360 minutes at six centers.
2 Patients and methods
The study included 131 hospitalized patients
between the 18th and 38th week of pregnancy
(mean: 32.6) in which tocolytic treatment was
indicated because of premature uterine contrac-
tions. Sixty-six of these patients received fenot-
erol depot and 65 patients received fenoterol.
The patients were allocated to one or the other
group according to a valid randomization plan.
The patients in the fenoterol depot group re-
ceived three fenoterol capsules* containing fen-
oterol with a total dose of 21 mg only at the
first administration. The second and third ap-
plications were made with placebos.
* Partusisten Depot Perlongette®, Boehringer Ingel-
heim
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In the fenoterol group, a capsule* containing
7.5 mg fenoterol and two placebos were ad-
ministered at each of the three applications, so
that in all 22.5 mg of fenoterol were adminis-
tered.
Fenoterol was used in the form of small film
tablets in an immediately dissolvable gelatine
capsule. A fenoterol depot capsule consisted of
four such film tablets, one 2.5 g tablet which
released fenoterol without delay, and the three
remaining 1.5 mg tablets which released the
fenoterol continuously and slowly. The fenot-
erol capsule consisted of three 2.5 mg film tab-
lets. As with the conventional Partusisten tablet
on the market, it released fenoterol without
delay. The placebo capsule was identical in
appearance and taste with the two true prepara-
tions, but did not contain any fenoterol.
An initial situation which was comparable for
the two groups was attained in a clinically
proved fashion by intravenous tocolysis with
Partusiten in a dosage of 1 — 3 g/min over the
duration of 30 minutes. The duration of the
investigation was 360 minutes. The correspond-
ing preparations were administered orally 5,
120 and 240 minutes after beginning of infu-
sion.
For comparative evaluation of fenoterol depot
with fenoterol, duration of contraction, fre-
quency of uterine contractions per 10 min (both
in accordance with the cardiotocogram (CTG)),
subjective intensity of uterine contractions (re-
ported by the patient as none, moderate, severe,
very severe and rated as 0, 1, 2, 3 respectively),
maternal pulse rate (MPRV), systolic and dias-
tolic blood pressure, fetal pulse rate (FPR, in
accordance with the CTG) as well as the tocoly-
tic efficacy and tolerance (both appraised by
the treating physician) were registered for com-
parison of fenoterol depot with fenoterol. In
addition, the side effects of the two prepara-
tions were documented.
Analogous to the Partusisten® tablet with regard to
release of fenterol.
The duration of contraction was evaluated ac-
cording to two criteria: as "mean duration of
contraction per overall group" and as "mean
duration of the single contraction". In the for-
mer, all contraction times of all patients investi-
gated including those with a value "0" (no
contraction at the time of measurement) was
added together for each of the defined measure-
ment times and averaged over the total number
of patients of the respective group. In the
second criterion, only those patients of the
group in whom measurable contractions were
present at the fixed measurement time were
considered. Prior value (before the beginning
of infusion), 30 minutes after the beginning of
infusion (end of infusion), 90 minutes (second
oral administration), 210 minutes (third oral
administration) and 330 minutes (end of the
trial) after the end of infusion were determined
as measurement times. Since contractions were
not present at all five measurement times in
one and the same patient, the corresponding
mean values were mainly not obtained in the
same patients. In order to be able to compare
the mean value of the respective measurement
time with the pretrial mean value in the same
patients, only those patients with measurable
uterine contraction were considered for the cal-
culation of the pretrial mean value (in whom
contractions had been present at the respective
measurement times. The value obtained at each
of the four measurement times after the end of
infusion was compared with the corresponding
pretrial value. The values·, for the frequency
of uterine contractions" for ten minutes were
extrapolated to the number of uterine contrac-
tions per hour.
The results from the two investigative group
were compared with each other and evaluated
statistically by means of the chi square test for
the strength of uterine contractions and the side
effects.
In the fenoterol depot group, the data of 60
out of the total of 66 and in the fenoterol group
the data of 56 or 58 out of the 65 patients
included in this study could be evaluated from
a statistical point of view. All patients were
registered with regard to the side effects.
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3 Results
3.1 Tocolytic effect
Mean duration of contraction per overall group:
In the fenoterol depot group, the mean duration
of contraction under the 30-minute Partusisten
infusion fell from 58.8 sec to 12.8 sec or by
78.2% of the initial value (figure 1). Up to the
end of the investigation, this lowering under
the single effect of the single dose of fenoterol
depot was maintained within a small range of
variation with a maximum decrease to 9.0 sec
(84.7%) and was only 9.8 sec at the end of the
investigation (83.3% under the pretrial value).
The mean duration of contraction fell in the
fenoterol group from 58.5 sec to 11.9 sec
(79.9% reduction) (figure 1) under the 30-min-
ute Partusisten infusion and remained at this
low level with a maximum decrease to 9 sec
(84.4%). At the end of the investigation, the
mean duration of contraction was 10.7 sec
(81.7% lowering compared to the initial value).
1 PARTUSISTEN I N F U S I O N
ORAL APPLICATION J
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Figure 1. Influence of the initial Partusisten infusion and
the two fenoterol test preparations on the mean duration
of contraction per overall group (explanation in the
text).
Mean duration of the individual contraction: In
the fenoterol depot group, the mean duration
of the individual contraction after the end of
the initial 30-minute Partusisten infusion fell by
42.9% from 73.7 sec to 42.1 sec. It remained
at a low level with a maximum of 49.5 sec (90
minutes after the end of the infusion) up to the
end of the observation period without a fresh
administration of fenoterol. The mean duration
of the individual contraction was reduced by
28.5% from 68 sec to 48.6 sec in the fenoterol
group at the end of infusion. In the further
course of the investigation under oral adminis-
tration alone, it rose to values between 66.6 sec
and 56.0 sec, but remained 5.1 to 16.7% below
the respective pretrial value (figure 2, table I).
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Figure 2. Percentage alteration of the mean duration
of the single contraction under influence of the initial
Partusisten infusion and the two fenoterol test prepara-
tions (explanation in the text).
The maximum difference (25.7%) of the mean
duration of the individual contraction between
the fenoterol depot group and the fenoterol
group was attained 90 minutes after the end of
infusion. It was 14.1% 330 minutes after the
end of infusion (table I). The mean duration of
contraction in the fenoterol depot group always
demonstrated a higher reduction compared to
the fenoterol group. Neither for a mean dura-
tion of contraction per overall group nor for
the mean duration of the individual contraction
was there a statistically significant difference
between the groups for the six measurement
times considered.
Frequency of uterine contractions: The level of
14.2 uterine contractions per hour present in
the fenoterol depot group before the beginning
of the 30-minute Partusisten infusion could be
lowered to a mean value of 2.8 contractions per
hour (80.3% of the initial value) after the end
of the infusion. Under the action of a single
dose of fenoterol depot alone, the frequency of
J. Perinat. Med. 15 (1987)
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Table I. Reduction of the mean duration of the individual contractions compared to the respective previous values
(before the beginning of the Partusisten infusion) in the fenoterol depot group and fenoterol group at different
times at the end of the initial Partusisten infusion with comparison of the two preparations.
Mean dura- Differ- n







end of infusion 48.6
before infusion 70.2
5.1 20
90 min after the
end of infusion 66.6
before infusion 62.1
7.6 14
210 min after the
end of infusion 57.4
before infusion 67.2
16.7 11
330 min after the
end of infusion 56.0
uterine contractions fell to 1.3 contractions per
hour (90.8% of the initial value) by the end of
the investigation (figure 3).
A mean frequency of uterine contractions of
13.0 contractions per hour previously present
in the fenoterol group was reduced to a mean
frequency of 1.5 contractions per hour (88.5%
of the initial value) under the 30-minute Partu-
sisten infusion. In the further course, there was
no noteworthy elevation of the frequency of
uterine contractions (figure 3). This was 1.6
contractions per hour (reduction by 87.7% of
the initial value) at the end of the investigation.
There was no significant difference in favor of
the fenoterol depot for the measurement times
up to 300 min after the end of the 30-minute
infusion, and a significant difference at the 10%
level at the end of the investigation.
Mean dura- Differ- n Difference between
tion of the ence the actual duration
single con- % of contraction be-
traction (sec) tween the fenoterol
in fenoterol group and the fe-
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Figure 3. Effect of the initial Partusisten infusion and
the two fenoterol test preparations on frequency of
uterine contractions.
Intensity of uterine contractions: Before the be-
ginning of the 30-minute Partusisten infusion,
the mean intensity of labor pains evaluated
subjectively by the patients was 1.4 in both
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groups. The intensity of uterine contractions
was reduced immediately after the end of infu-
sion in the two groups to values of 0.3 to 0.4
and remained at values between 0.2 and and
0.3 up to the end of the investigation.
3.2 Effects on the cardiovascular system in
mother and fetus
Maternal pulse rate (MPR): The mean MPR
in the fenoterol depot group was 99.6 beats/
min at the end of the Partusisten infusion (pre-
trial value 91.3 beats/min). It reached a max-
imum of 104.6 beats/min 150 min after the end
of infusion and was at 101.6 beats/min at the
end of investigation (figure 4). In the fenoterol
group, the mean MPR immediately after the
30-minute Partusisten infusion rose from an
initial value of 90.3 to 103.3 beats/min. Under
the further oral application, the mean MPR
remained in this range with a maximum of
105.6 beats/min (figure 4). For the time 30
minutes after the end of infusion, there was a
statistically significant difference between the
two groups at the 5% level. There was a higher
increase of MPR in the fenoterol group than
in the fenoterol depot group. There was no
significant difference for all other measurement
times.
In both groups, the systolic blood pressure did
not show any clinically relevant alterations dur-
ing treatment with the two preparations. The
mean value was between 116.9 and 118.4
mmHg (pretrial value 119.4 mmHg) in the fen-
oterol depot group; in the fenoterol group, it
was between 114.0 and 117.5 mmHg (pretrial
value 115.9) (figure 5). In the two groups, the
diastolic blood pressure showed a constant
course within a narrow range of variation with
a slight tendency to lowering compared to the
pretrial value. The lowest mean value was 64.4
mmHg in the fenoterol depot group and the
highest mean value was 67.9 mmHg (pretrial
value 70.8 mmHg). For the fenoterol group,
the corresponding values were 61.8 mmHg and
67.6 mmHg (preterial value 63.9 mmHg). There
was no significant difference at the 10% level
between the two groups for the systolic blood
pressure, and in the case of the diastolic blood
pressure there was a significant difference at
the 10% level only for the fifth of the six meas-
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Figure 4. Behavior of maternal pulse rate (MPR) under
the initial Partusisten infusion and the treatment with
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Figure 5. Behavior of maternal systolic blood pressure
under the initial Partusisten infusion and the treatment
with the two fenoterol test preparations.
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Figure 6. Behavior of maternal diastolic blood pressure
under the initial Partusisten infusion and the treatment
with the two fenoterol test preparations.
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Fetal pulse rate (FPR): As in the maternal
cardiovascular parameters described above, the
mean FPR in the two groups also demonstrated
an approximately parallel curve course with a
slight tendency to rise (figure 7). In the fenot-
erol depot group, the FPR before the beginning
of infusion was 147.8 beats/min, and rose to
148.5 beats/min up to the end of infusion, and
afterwards. rose to 159.1 beats/min 210 min
later. The FPR was 158.1 beats/min at the end
of the investigation. In the fenoterol group, it
rose to 151.7 beats/min at the end of the 30-
minute Partusisten infusion (pretrial value
146.3 beats/min). At the end of the investiga-
tion, it rose to 160.3 beats/min with a maximum
mean value of 160.8 beats/min 300 min after
the end of infusion. There was no statistically
significant difference between the two groups
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Figure 7. Behavior of the fetal pulse rate (FPR) under
the initial Partusisten infusion and treatment with the
two fenoterol test preparations.
3.3 Tocolytic efficacy
In 42 (70%) of 60 patients in the fenoterol
depot group and in 40 (69%) of the 58 patients
in the fenoterol group, the tocolytic efficacy
was rated as "good", in 14 and 15 respectively
as "satisfactory" and in four and three respec-
tively as "not satisfactory". There was no sta-
tistically significant difference between the two
groups.
3.4 Tolerance
In 45 patients (75%) of the fenoterol depot
group and 42 patients (71%) of the fenoterol
group, a good tolerance and in 12 and 14
patients respectively a satisfactory tolerance
was recorded. In three patients in each of the
two groups, the tolerance was designated as not
satisfactory. A statistically significant differ-
ence could not be found between the two
groups.
3.5 Side effects
In the fenoterol depot group, side effects were
observed in 17 out of 66 patients (26%) and in
the fenoterol group in 20 out of 54 patients
(31%) (table II). Cardiovascular symptoms and
tremor were unequivocally most prominent in
the two groups. The total number of side effects
reported is greater than that of the patients,
since several side effects often occurred in one
and the same patient.
Table II. Side effects of the two fenoterol preparations
with delayed and undelayed release of substance and
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4 Discussion
A comparison of the tocolytic properties of the
two preparations showed that both the single
oral dose of fenoterol depot and three separate
doses of fenoterol resulted in maintenance of
constancy of the parameters associated with
uterine contractions attained by partusisten in-
fusion at a low level over a period of six hours.
Fenoterol depot was equivalent or indeed
slightly superior to fenoterol in this respect at
some measurement times. Comparably good
tocolytic effects with a fenoterol depot prepara-
tion have been observed by other authors [8].
It may be assumed that this effect is attributable
to the action of the oral therapy alone, since a
relevant influence of the I. V. treatment persist-
ing beyond the duration of the infusion is
hardly to be expected because of the short fen-
oterol halflife of 22 minutes.
The first oral dose of the two preparations was
made for both groups at the same time, about
30 minutes before the end of the infusion, as has
been recommended for a long time by various
authors [6, 10, 121, 13, 14]. As with the initial
Partusisten infusion, this oral administration
served to produce comparable initial condi-
tions, since it could not have any significant
effect on the reduction of uterine contractions
during the remaining period of infusion. The
same amount of active substances was released
without delay in both fenoterol preparations.
The tolerance of the fenoterol depot group
proved to be equally, good, if not indeed some-
what better than fenoterol, which correlates
well with results of other investigators [8]. An
evaluation of the duration of the contractions
of the basis of an external tocogram appeared
to us to be justifiable, since in each patient the
CTG was continuously plotted over the entire
observation period, and the study thus involved
a longitudinal comparison in relation to the
respective pretrial value. With regard to the
extrauterine effects (MPR, FPR, blood pres-
sure), these showed equal or smaller variations
in the fenoterol depot group than in the fenot-
erol group. Similar results have also been re-
ported earlier [2, 11]. In the side effects, which
were slightly less in the fenoterol depot group
than in the fenoterol group, cardiovascular
symptoms and tremor were the most promi-
nent. These are also to be expected in beta-
mimetic therapy [10]. On the basis of this inves-
tigation as well as earlier studies [2, 8, 11], it
can be observed overall that the present results
on the fenoterol depot preparation encourage
its clinical application.
Summary
In a double-blind randomized study, the effect of a single
dose of a fenoterol preparation with delayed release of
active substance (designated as fenoterol depot) was
compared with a fenoterol product with undelayed re-
lease of active substance (designated as fenoterol) in two
groups respectively comprising 66 and 65 female patients
with premature uterine contractions.
The fenoterol depot was administered p. o. in a single
total dose of 21 mg at the beginning of an investigation
period of 360 minutes and the fenoterol was adminis-
tered p. o. within 235 minutes in three identical consecu-
tive doses resulting in a total dose of 22.5 mg.
The increased uterine activity present at the beginning
was markedly lowered by an initial intravenous infusion
of Partusisten. After administration of the two oral
preparations, the uterine contractions remainded at the
low level achieved.
The fenoterol depot was slightly superior to fenoterol
with regard to the reduction of the duration of contrac-
tions: the difference in the inhibition of the duration of
the contraction between the two preparations was a
maximum of 25.7% in favor of fenoterol depot. The
frequency of uterine contraction was substantially re-
duced by both preparations, but to a greater extent by
the depot form. The tocolytic efficacy and the tolerance
were rated as "good" in 70% and 75% respectively with
fenoterol depot and in 69% and in 71% respectively in
the case of fenoterol. The maternal pulse rate remained
at the level reached at the end of Partusisten infusion
with the two preparation, and the blood pressure fluctu-
ated slightly within the normal range. The fetal pulse
rate demonstrated a slight rise within the normal range
in the two groups. In the two groups of patients, there
were occasional side effects (most prominently cardio-
vascular symptoms and tremor). The rate of side effects
was somewhat less under fenoterol depot.
Keywords: Prematurity, tocolytic agent, uterine contractions.
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Zusammenfassung
Fenoterol-Depot und Fenoterol bei vorzeitiger Wehentä-
tigkeit — eine multizentrische Doppelblindstudie im Ver-
gleich
In einer doppelblinden, randomisierten Studie wurde die
einmalige Gabe eines Fenoterol-Präparates mit verzö-
gerter Wirkstoff-Freigabe (Fenoterol-Depot) mit einem
Fenoterol-Präparat mit unverzögerter Wirkstoff-Frei-
gabe (Fenoterol) an zwei Kollektiven von 66 bzw. 65
Patientinnen mit vorzeitiger Wehentätigkeit verglichen.
Das Fenoterol-Depot wurde in einer einmaligen Ge-
samtdosis von 21 mg am Anfang eines Untersuchungs-
zeitraums von 360 Minuten und das Fenoterol innerhalb
von 235 Minuten in drei identischen konsekutiven Ga-
ben in einer Gesamtdosis von 22,5 mg oral verabreicht.
Die anfänglich bestehende, wesentlich erhöhte uterine
Aktivität wurde durch eine initiale intravenöse Partusi-
sten-Infusion deutlich gesenkt. Nach Gabe beider oraler
Präparate blieb die Wehentätigkeit auf dem erreichten
niedrigen Niveau.
Das Fenoterol-Depot war hinsichtlich der Reduktion
der Kontraktionsdauer dem Fenoterol leicht überlegen:
der Unterschied in der Hemmung der Kontraktions-
dauer zwischen den beiden Präparaten betrug im Maxi-
mum 25,7% zugunsten des Fenoterol-Depots. Die We-
henfrequenz wurde mit beiden Präparaten maßgeblich,
mit der Depot-Form jedoch ausgeprägter reduziert. Die
tokolytische Wirksamkeit und die Verträglichkeit wur-
den bei Fenoterol-Depot zu 70 bzw. 75% und beim
Fenoterol zu 69 bzw. 71% mit „gut" beurteilt. Die
mütterliche Herzfrequenz verblieb bei beiden Präparaten
auf dem am Ende der Partusisten-Infusion erreichten
Niveau, der Blutdruck schwankte geringfügig innerhalb
des Normbereichs. Die fetale Herzfrequenz zeigte bei
beiden Kollektiven einen im Normbereich liegenden ge-
ringen Anstieg. In beiden Patientinnen-Kollektiven tra-
ten vereinzelt Nebenwirkungen auf (vordergründig kar-
diovaskuläre Symptome und Tremor), wobei unter dem
Fenoterol-Depot die Nebenwirkungsrate etwas geringer
ausfiel.
Schlüsselwörter: Frühgeburtlichkeit, Tokolytikum, Wehentätigkeit.
Resume
Fenoterol et fenoterol retard en cas de contractions uteri-
nes prematurees — une etude comparative en double
aveugle multicentrique
On a compare dans une etude randomisee en double
aveugle, l'effet d'une dose unique de fenoterol ä action
retard (fenoterol retard), ä l'effet de fenoterol sans libe-
ration retardee (fenoterol) dans deux groupes compre-
nant respectivement 66 et 65 patientes presentant prema-
turement des contractions uterines.
Le fenoterol retard a ete administre per os ä dose unique
de 21 mg au debut de la periode d'exploration de 360
minutes, et le fenoterol per os en trois doses consecutives
identiques pendant 235 minutes ä la dose totale de 22,5
mg. Une perfusion intra-veineuse initiale de Partusisten
a nettement diminue l'activite uterine notablement aug-
mentee au debut. Apres administration des deux prepa-
rations par voie orale, les contractions uterines sont
demeurees au faible niveau obtenu.
Le fenoterol retard est legerement superieur au fenoterol
pour la diminution de la duree des contractions: la
difference dans l'inhibition de la duree des contractions
entre les deux preparations est au maximum de 25,7%
en faveur du fenoterol retard. La frequence des contrac-
tions uterines est notablement diminuee par les deux
preparations, mais plus par la forme retard. L'efficacite
tocolytique et la tolerance sont notees comme «bonnes»
dans respectivement 70% et 75% avec le fenoterol retard
et dans respectivement 69% et 71% avec le fenoterol.
Le pouls maternel est demeure au meme niveau que
celui obtenu ä la fin de la perfusion de Partusisten,
avec les deux preparations, et la pression arterielle a
legerement varie dans les limites normales. Le rythme
cardiaque foetal a montre une legere acceleration ä l'inte-
rieur des limites normales, dans les deux groupes. Dans
les deux groupes de patientes, il y a eu quelques effets
secondaires (le plus souvent symptomes cardio-vascu-
laires et tremblements). La frequence des effets secondai-
res a ete moindre avec le fenoterol retard.
Mots-cles: Agents tocolytiques, contractions uterines, prematurite.
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